Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 November 2022 | Story Leonie Bolleurs | Photo Leonie Bolleurs
UFS green concrete
The Department of Engineering Sciences (EnSci) welcomes collaborations with other departments at the UFS. Pictured here are, from the left: Louis Lagrange, Head of EnSci, Prof Kahilu Kajimo-Shakantu, Head of the Department of Quantity Surveying and Construction Management, Dr Abdolhossein Naghizadeh, and Megan Welman-Purchase, analytical scientist in the Department of Geology.

More than 30 million tonnes of fly ash (residue from coal combustion in power plants) are generated in South Africa annually, with 96% of that being disposed of in landfills. There is thus more than enough of this key ingredient to produce green concrete. 

Green concrete, so called due to its environmentally friendly benefits, is an eco-friendly alternative to conventional concrete based on the Portland cement binder. During the production of green concrete, less carbon dioxide is released into the atmosphere than with the production of ordinary Portland cement (OPC). The latter accounts for up to 8% of all global carbon emissions.

Successful tests

In the Green Concrete Lab, established in 2021 within the Department of Engineering Sciences (EnSci) on the Bloemfontein Campus of the University of the Free State (UFS), Dr Abdolhossein Naghizadeh, Senior Lecturer, researcher, and engineer, is working on green cement and concrete projects.

He uses ‘geopolymer’ technology and a mix of waste materials, alkaline solutions, and recycled aggregates to form concrete mixtures that can provide properties similar to conventional concrete.

Besides being a synthesised inorganic material (not a petrochemical product), the geopolymer cement he introduced has the following properties: it is made from a reaction between aluminosilicate materials and strong alkalis (5-7% of the concrete mixture), it uses water and by-products as raw materials, it does not calcinate lime, thus giving it a low carbon emission, and it is also beneficial from a waste management point of view. 

The waste materials used can include waste from industrial and agricultural sources, such as fly ash, rice husk ash, sugar-cane bagasse, or corncob ash, as well as natural materials such as volcanic ash. In South Africa, sufficient amounts of industrial and agricultural waste are available. 

“So far, we have successfully tested various types of green concrete based on different waste materials,” says Dr Naghizadeh. 

Besides researching the green mixture proportions in the lab, Dr Naghizadeh and his students focused their attention on establishing the strength, durability, workability, and production cost of the product. 

They compared green concrete with conventional concrete. Green concrete’s workability is slightly lower (but he believes that with appropriate mix design it can be corrected), and it has a much higher compressive strength (50-90 MPa), a smaller carbon footprint, and comparable production costs to conventional concrete (depending on the mix design). A very high level of resistance against alkali-silica reaction (concrete cancer) is also present, as well as resistance to carbonation, sulphate attack, and acid attack.
So far, we have successfully tested various types of green concrete based on different waste materials.– Dr Naghizadeh. 

He explains, “The superior durability performance of green concrete is related to its chemical compositions and microstructure. For example, the lack of calcium content in the composition provides better resistance to alkali-silica reaction. At the same time, stronger bonds between elements and polymeric microstructure provide better resistance against acids and fire.”

With all the work and research of the past year and a half, Dr Naghizadeh says they are at the stage where they can prescribe green concrete production recipes for the industry parties based on the specified application and the materials they have.

Biggest accomplishments

“We transferred most of the experimental works to the Green Concrete Lab at the beginning of 2022, which improved our productivity tremendously. Since then, nine journal papers and three peer-reviewed conference papers have been published as outputs of the research projects. Currently, there are also multiple publications under review or in the development stages,” says Dr Naghizadeh.

In addition to him, there are three master's students and one research associate working on their own individual projects.

The department is very proud of its research outputs. Dr Naghizadeh was either author or co-author of all 12 research papers. The focus of these papers was mostly on the formulation of green concrete, based on locally available agricultural waste materials, the formulation of one-part geopolymer cement (when aluminosilicate raw material is replaced with pre-activated aluminosilicate material, water can be used instead of alkali solution), and the development of ambient-cured green concrete (replacing the aluminosilicate raw material with a blend of materials).

Dr Naghizadeh is also the project leader of a group of scientists from local and international universities who are researching sustainable construction materials. These institutions include the Universities of Johannesburg, KwaZulu-Natal, Yaoundé in Cameroon, Erzurum Technical University in Turkey, as well as Nelson Mandela University and the Central University of Technology, which recently came on board. 

 


 


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept